Renin: friend or foe?

被引:72
作者
Brown, Morris J. [1 ]
机构
[1] Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England
关键词
D O I
10.1136/hrt.2006.107706
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renin maintains blood pressure through vasoconstriction when there is inadequate salt to maintain volume. In populations where blood pressure is more often high than low, and vascular death more common than haemorrhage or dehydration, therapeutic reductions in renin secretion or response are valuable. Whether long- term benefits are due entirely to blood pressure reduction remains unproved. The pathway can be blocked at its rate- limiting step ( beta blockade or direct renin inhibition), the synthesis of the active product, angiotensin II, or at the receptor for angiotensin. Because renin and sodium are the two main factors in blood pressure control, and renin levels vary inversely with sodium load, blood pressure control requires a combination of natriuresis and blocking the consequential increase in renin activity. Being a large and stable molecule, renin is among the easiest and cheapest of hormone measurements. Understanding the simple biochemistry and physiology of renin permits optimal use of the drugs acting to raise or suppress this hormone.
引用
收藏
页码:1026 / 1033
页数:8
相关论文
共 82 条
[31]   Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II -: From large arteries to the microcirculation [J].
Henrion, D ;
Kubis, N ;
Lévy, BI .
HYPERTENSION, 2001, 38 (05) :1150-1157
[32]   INVESTIGATION OF PLASMA-RENIN ACTIVITY UNDER DIFFERENT CONDITIONS FOR DRAWING AND STORING OF BLOOD-SAMPLE [J].
HERKNER, K ;
HERKNER, C ;
FINK, M .
CLINICA CHIMICA ACTA, 1983, 127 (01) :131-135
[33]   Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing [J].
Hood, S ;
Cannon, J ;
Foo, R ;
Brown, M .
CLINICAL MEDICINE, 2005, 5 (01) :55-60
[34]   The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio [J].
Hood, Susan J. ;
Taylor, Kevin P. ;
Ashby, Michael J. ;
Brown, Morris J. .
CIRCULATION, 2007, 116 (03) :268-275
[35]   Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension [J].
Ichihara, A ;
Kaneshiro, Y ;
Takemitsu, T ;
Sakoda, M ;
Suzuki, F ;
Nakagawa, T ;
Nishiyama, A ;
Inagami, T ;
Hayashi, M .
HYPERTENSION, 2006, 47 (05) :894-900
[36]   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].
Julius, S ;
Kjeldsen, SE ;
Weber, M ;
Brunner, HR ;
Ekman, S ;
Hansson, L ;
Hua, TS ;
Laragh, J ;
McInnes, GT ;
Mitchell, L ;
Plat, F ;
Schork, A ;
Smith, B ;
Zanchetti, A .
LANCET, 2004, 363 (9426) :2022-2031
[37]   Nephron number in patients with primary hypertension. [J].
Keller, G ;
Zimmer, G ;
Mall, G ;
Ritz, E ;
Amann, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) :101-108
[38]   RENIN PROFILING FOR DIAGNOSIS AND TREATMENT OF HYPERTENSION [J].
LARAGH, JH ;
LETCHER, RL ;
PICKERING, TG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1979, 241 (02) :151-156
[39]   Genetic deletion of AT2 receptor antagonizes angiotensin II-induced apoptosis in fibroblasts of the mouse embryo [J].
Li, WG ;
Ye, YH ;
Fu, B ;
Wang, JZ ;
Yu, LF ;
Ichiki, T ;
Inagami, T ;
Ichikawa, I ;
Chen, XM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (01) :72-76
[40]  
Lim PO, 1999, BRIT J CLIN PHARMACO, V48, P756